TABLE OF CONTENTS
1 INTRODUCTION 48
1.1 OBJECTIVES OF THE STUDY 48
1.2 MARKET DEFINITION 48
1.3 OVERVIEW OF THE NORTH AMERICA BREAST CANCER DIAGNOSTIC MARKET 48
1.4 CURRENCY AND PRICING 50
1.5 LIMITATIONS 50
1.6 MARKETS COVERED 50
2 MARKET SEGMENTATION 54
2.1 MARKETS COVERED 54
2.2 GEOGRAPHICAL SCOPE 55
2.3 YEARS CONSIDERED FOR THE STUDY 56
2.4 DBMR TRIPOD DATA VALIDATION MODEL 57
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 60
2.6 MULTIVARIATE MODELLING 61
2.7 MARKET END USER COVERAGE GRID 62
2.8 TEST TYPE LIFELINE CURVE 63
2.9 DBMR MARKET POSITION GRID 64
2.10 VENDOR SHARE ANALYSIS 65
2.11 SECONDARY SOURCES 66
2.12 ASSUMPTIONS 66
3 EXECUTIVE SUMMARY 67
4 PREMIUM INSIGHTS 69
4.1 PESTEL ANALYSIS 70
4.2 PORTER'S 5 FORCES 71
5 EPIDEMIOLOGY 72
6 INDUSTRIAL INSIGHTS 73
7 REGULATORY FRAMEWORK 74
8 MARKET OVERVIEW 76
8.1 DRIVERS 78
8.1.1 LAUNCH OF TECHNOLOGICALLY ADVANCED DIAGNOSIS & THERAPEUTICS TO AID GROWTH 78
8.1.2 INCREASING PREVALENCE OF BREAST CANCER 78
8.1.3 GROWING IMPORTANCE OF WOMEN'S HEALTH 79
8.1.4 RISING AWARENESS TOWARDS THE BREAST CANCER 79
8.2 RESTRAINTS 80
8.2.1 ADVERSE EFFECTS OF BREAST CANCER THERAPEUTICS 80
8.2.2 HIGH COST OF THE IMAGING SYSTEMS 80
8.3 OPPORTUNITIES 81
8.3.1 INITIATIVES TAKEN BY THE GOVERNMENT 81
8.3.2 STRATEGIC INITIATIVES TAKEN BY THE KEY MARKET PLAYERS 81
8.3.3 GROWTH IN RESEARCH AND DEVELOPMENT OF BREAST CANCER 82
8.4 CHALLENGES 82
8.4.1 LACK OF DIAGNOSTIC INFRASTRUCTURE 82
8.4.2 LACK OF SKILLED PROFESSIONALS FOR PROPER DIAGNOSIS OF BREAST CANCER 83
9 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE 84
9.1 OVERVIEW 85
9.2 IMAGING 88
9.2.1 IONIZING BREAST IMAGING TECHNOLOGIES 89
9.2.1.1 FULL-FIELD DIGITAL MAMMOGRAPHY (FFDM) 90
9.2.1.2 ANALOG MAMMOGRAPHY 90
9.2.1.3 3D BREAST TOMOSYNTHESIS 90
9.2.1.4 POSITRON EMISSION TOMOGRAPHY/ COMPUTED TOMOGRAPHY (PET/CT) 90
9.2.1.5 MOLECULAR BREAST IMAGING/ BREAST SPECIFIC GAMMA IMAGING (MBI/BSMI) 90
9.2.1.6 POSITRON EMISSION MAMMOGRAPHY 90
9.2.1.7 OTHERS 90
9.2.2 NON-IONIZING IMAGING TECHNOLOGIES 90
9.2.2.1 OPTICAL IMAGING 91
9.2.2.2 BREAST ULTRASOUND 91
9.2.2.3 BREAST MRI (MAGNETIC RESONANCE IMAGING) 91
9.2.2.4 AUTOMATED WHOLE BREAST ULTRASOUND (AWBU) 91
9.2.2.5 BREAST THERMOGRAPHY 92
9.2.3 BIOPSY 92
9.2.3.1 SURGICAL BIOPSY 93
9.2.3.2 FINE NEEDLE ASPIRATION BIOPSY 93
9.2.3.3 CORE NEEDLE BIOPSY 93
9.2.3.4 IMAGE-GUIDED BIOPSY 93
9.2.3.5 SENTINEL LYMPH NODE BIOPSY 94
9.2.4 GENOMIC TEST 94
9.2.4.1 MOLECULAR TESTING 95
9.2.4.1.1 PD-L1 96
9.2.4.1.2 MICROSATELLITE INSTABILITY-HIGH (MSI-H) OR DNA MISMATCH REPAIR DEFICIENCY (DMMR) 96
9.2.4.1.3 NTRK GENE FUSIONS 96
9.2.4.1.4 PI3KCA GENE MUTATION 96
9.2.4.2 MAMMAPRINT 96
9.2.4.3 ONCOTYPE DX 96
9.2.4.4 OTHERS 96
9.3 BLOOD TEST 97
9.4 OTHERS 98
10 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE 99
10.1 OVERVIEW 100
10.2 INVASIVE DUCTAL CARCINOMA 103
10.3 DUCTAL CARCINOMA IN SITU 103
10.4 INFLAMMATORY BREAST CANCER 104
10.5 METASTATIC BREAST CANCER 105
11 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET, BY END USER 106
11.1 OVERVIEW 107
11.2 HOSPITALS 109
11.3 DIAGNOSTICS CENTERS 110
11.4 CLINICS 111
11.5 RESEARCH & ACADEMIC INSTITUTES 111
11.6 OTHERS 112
12 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 114
12.1 OVERVIEW 115
12.2 DIRECT TENDER 118
12.3 RETAIL SALES 118
12.4 OTHERS 119
13 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET, BY REGION 120
13.1 NORTH AMERICA 121
13.1.1 U.S. 129
13.1.2 CANADA 135
13.1.3 MEXICO 141
14 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 147
14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 147
15 SWOT ANALYSIS 148
16 COMPANY PROFILE 149
16.1 HOLOGIC, INC. 149
16.1.1 COMPANY SNAPSHOT 149
16.1.2 REVENUE ANALYSIS 149
16.1.3 COMPANY SHARE ANALYSIS 150
16.1.4 PRODUCT PORTFOLIO 150
16.1.5 RECENT DEVELOPMENTS 151
16.2 SIEMENS HEALTHCARE GMBH 152
16.2.1 COMPANY SNAPSHOT 152
16.2.2 REVENUE ANALYSIS 153
16.2.3 COMPANY SHARE ANALYSIS 153
16.2.4 PRODUCT PORTFOLIO 154
16.2.5 RECENT DEVELOPMENTS 154
16.3 F. HOFFMANN- LA ROCHE LTD 155
16.3.1 COMPANY SNAPSHOT 155
16.3.2 REVENUE ANALYSIS 155
16.3.3 COMPANY SHARE ANALYSIS 156
16.3.4 PRODUCT PORTFOLIO 156
16.3.5 RECENT DEVELOPMENTS 157
16.4 KONINKLIJKE PHILIPS N.V. 158
16.4.1 COMPANY SNAPSHOT 158
16.4.2 REVENUE ANALYSIS 158
16.4.3 COMPANY SHARE ANALYSIS 159
16.4.4 PRODUCT PORTFOLIO 159
16.4.5 RECENT DEVELOPMENTS 160
16.5 ABBOTT 161
16.5.1 COMPANY SNAPSHOT 161
16.5.2 REVENUE ANALYSIS 161
16.5.3 COMPANY SHARE ANALYSIS 162
16.5.4 PRODUCT PORTFOLIO 162
16.5.5 RECENT DEVELOPMENTS 162
16.6 ABACUS ALS 163
16.6.1 COMPANY SNAPSHOT 163
16.6.2 PRODUCT PORTFOLIO 163
16.6.3 RECENT DEVELOPMENTS 163
16.7 BD 164
16.7.1 COMPANY SNAPSHOT 164
16.7.2 REVENUE ANALYSIS 164
16.7.3 COMPANY SHARE ANALYSIS 165
16.7.4 PRODUCT PORTFOLIO 165
16.7.5 RECENT DEVELOPMENTS 165
16.8 BIOCEPT, INC. 166
16.8.1 COMPANY SNAPSHOT 166
16.8.2 REVENUE ANALYSIS 166
16.8.3 PRODUCT PORTFOLIO 167
16.8.4 RECENT DEVELOPMENTS 167
16.9 BIOMRIEUX 168
16.9.1 COMPANY SNAPSHOT 168
16.9.2 REVENUE ANALYSIS 168
16.9.3 PRODUCT PORTFOLIO 169
16.9.4 RECENT DEVELOPMENTS 169
16.10 BIO-RAD LABORATORIES, INC. 170
16.10.1 COMPANY SNAPSHOT 170
16.10.2 REVENUE ANALYSIS 170
16.10.3 PRODUCT PORTFOLIO 171
16.10.4 RECENT DEVELOPMENT 171
16.11 CEPHEID 172
16.11.1 COMPANY SNAPSHOT 172
16.11.2 REVENUE ANALYSIS 172
16.11.3 PRODUCT PORTFOLIO 173
16.11.4 RECENT DEVELOPMENT 173
16.12 EXACT SCIENCES CORPORATION 174
16.12.1 COMPANY SNAPSHOT 174
16.12.2 REVENUE ANALYSIS 174
16.12.3 COMPANY SHARE ANALYSIS 175
16.12.4 PRODUCT PORTFOLIO 175
16.12.5 RECENT DEVELOPMENTS 176
16.13 FUJIFILM CORPORATION 177
16.13.1 COMPANY SNAPSHOT 177
16.13.2 REVENUE ANALYSIS 177
16.13.3 PRODUCT PORTFOLIO 178
16.13.4 RECENT DEVELOPMENT 178
16.14 GENERAL ELECTRIC 179
16.14.1 COMPANY SNAPSHOT 179
16.14.2 REVENUE ANALYSIS 179
16.14.3 PRODUCT PORTFOLIO 180
16.14.4 RECENT DEVELOPMENTS 180
16.15 ILLUMINA, INC. 181
16.15.1 COMPANY SNAPSHOT 181
16.15.2 REVENUE ANALYSIS 181
16.15.3 PRODUCT PORTFOLIO 182
16.15.4 RECENT DEVELOPMENTS 182
16.16 MYRIAD GENETICS, INC. 183
16.16.1 COMPANY SNAPSHOT 183
16.16.2 REVENUE ANALYSIS 183
16.16.3 PRODUCT PORTFOLIO 184
16.16.4 RECENT DEVELOPMENT 184
16.17 NANOSTRING. 185
16.17.1 COMPANY SNAPSHOT 185
16.17.2 REVENUE ANALYSIS 185
16.17.3 PRODUCT PORTFOLIO 186
16.17.4 RECENT DEVELOPMENT 186
16.17.5 RECENT DEVELOPMENT 186
16.18 ONCOSTEM. 187
16.18.1 COMPANY SNAPSHOT 187
16.18.2 PRODUCT PORTFOLIO 187
16.18.3 RECENT DEVELOPMENT 187
16.19 PROVISTA DIAGNOSTICS. 188
16.19.1 COMPANY SNAPSHOT 188
16.19.2 PRODUCT PORTFOLIO 188
16.19.3 RECENT DEVELOPMENT 188
16.20 THERMO FISHER SCIENTIFIC INC. 189
16.20.1 COMPANY SNAPSHOT 189
16.20.2 REVENUE ANALYSIS 189
16.20.3 PRODUCT PORTFOLIO 190
16.20.4 RECENT DEVELOPMENT 190
17 QUESTIONNAIRE 191
18 RELATED REPORTS 194

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.